5631-96-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-Chloroethoxy)tetrahydro-2H-pyran is used as a synthetic intermediate for the development of new pharmaceutical compounds. Its ability to introduce a protected 2-hydroxyethyl group allows chemists to create diverse molecular structures with potential therapeutic applications.
Used in Chemical Synthesis:
In the field of chemical synthesis, 2-(2-Chloroethoxy)tetrahydro-2H-pyran is used as a key building block for constructing complex organic molecules. Its unique structural properties enable the formation of various functional groups, which can be further modified to create novel compounds with specific applications.
Used in Research and Development:
2-(2-Chloroethoxy)tetrahydro-2H-pyran is also utilized in research and development settings, where it aids in the exploration of new chemical reactions and the synthesis of innovative molecules. Its role in introducing a protected 2-hydroxyethyl group makes it a valuable tool for advancing scientific knowledge and discovering new applications in various industries.

InChI:InChI=1/C7H13ClO2/c8-4-6-10-7-3-1-2-5-9-7/h7H,1-6H2

Upstream product

• 110-87-2 3,4-dihydro-2H-pyran 
• 107-07-3 2-chloro-ethanol 

Downstream Products

• 4442-79-9 cyclohexylethan-1-ol 
• 196106-21-5 1-(2-iodophenoxy)-2-(tetrahydro-2H-2-pyranyloxy)ethane 
• 196106-20-4 1-[4-(tert-butyl)-2-iodophenoxy]-2-(tetrahydro-2H-2-pyranyloxy)ethane 
• 205381-75-5 4-benzyloxyphenoxyethyl tetrahydro-2H-pyran-2-yl ether 
• 864719-81-3 [2-(tetrahydro-2H-pyran-2-yloxy)ethoxy][(2R,3R)-3-(phenylmethoxy)(tetrahydro-2H-pyran-2-yl)]methane 
• 196106-33-9 C₂₆H₃₀O₅ 
• 1400998-10-8 1,4-di(2-tetrahydropyranyloxyethoxy)-2,3-benzenedicarbonitrile 
• 7541-49-3 3,7,11,15-tetramethyl-2-hexadecen-1-ol 

Relevant academic research and scientific papers

Derivative containing nitrogen heterocyclic rings and application of derivative in retinal neovascularization diseases

The invention discloses a derivative containing nitrogen heterocyclic rings and application of the derivative in retinal neovascularization diseases. The derivative has the biological structural formula shown in the description, wherein R1, R2, R3 and R4 are respectively and independently selected from -H or -CN. Under the same concentration of 5microg/mL, the growth inhibition ratios of the embodiment II, the embodiment III and the embodiment IV to HRCEC are superior to a monoclonal antibody drug Avastin. By injecting the compound into a vitreous body, the formation of pathologic new vesselscan be reduced, so that the derivative of the formula I or the salt of the derivative can be used for deeply researching and developing retinal neovascularization relevant diseases such as retinal vein occlusion, proliferative diabetic retinopathy, subretinal neovascular membrane, neovascular glaucoma, retinopathy of prematurity and proliferative vitreoretinopathy.

Nitrogen heterocycle containing derivatives and application thereof in retinal diseases

The invention discloses nitrogen heterocycle containing derivatives and an application thereof in retinal diseases. The nitrogen heterocycle containing derivatives have a structural formula which is described in the specification. In the structural formula, R1, R2, R3 and R4 are independently selected from the group consisting of -H and -F. The nitrogen heterocycle containing derivatives providedby an embodiment 1, an embodiment 2, an embodiment 3 and an embodiment4 of the invention have an HRCEC proliferation inhibition rate superior to the HRCEC proliferation inhibition rate of a monoclonalantibody medicine namely Avastin at the same concentration of 5 [mu]g/mL. According to the invention, after intravitreal injection administration, a compound provided by the invention can reduce pathological neovascularization; thus, the nitrogen heterocycle containing derivatives with a formula I or salts thereof provided by the invention are proved to be able to be used for in-depth research and development for treatment of retinal neovascularization related diseases, such as retinal vein occlusion, proliferative diabetic retinopathy, subretinal neovascular membrane, neovascular glaucoma, retinopathy of prematurity, proliferative vitreoretinopathy, etc.

BiCl3: A versatile catalyst for the tetrahydropyranylation and depyranylation of 1°,2°,3°, allylic, benzylic alcohols, and symmetric diols

Bismuth trichloride as mild reagent, has been found to be a worthful catalyst for tetrahydropyranylation of 1°,2°,3°, allylic, benzylic alcohols, and symmetric di-ols. At room temperature the reagent THP(3,4-dihydro-2H-pyran) was successfully employed as pyranylating agent in presence of BiCl3catalyst without the use of a solvent and the yields of the products were found to be 90-96%. Further, the depyranylation of alcohols was achieved in quantitative yield by simple addition of MeOH using the same catalyst. The developed method was showed good chemo-selectivity in symmetrical diols for mono THP protection.

Multi-gram synthesis of a porphyrazine platform for cellular translocation, conjugation to Doxorubicin, and cellular uptake

We report the synthesis of the near infrared (NIR) fluorescent porphyrazine (Pz) 285, with pendant hydroxyl groups, as a non-toxic platform for delivery of conjugated chemotherapeutic agents to tumor cells. Conjugation of Pz 285 to Doxorubicin via an acid

AI(OTf)3 - A highly efficient catalyst for the tetrahydropyranylation of alcohols under solvent-free conditions

A simple and highly efficient method has been developed for the tetrahydropyranylation of alcohols by their reaction with 3,4-dihydro-2H-pyran (DHP) using a catalytic amount (0.01-1 mol%) of aluminium triflate under solvent-free conditions. The effect of various factors like temperature, amount of the catalyst, and molar ratio of substrates on the reaction conditions has also been studied. The comparative study of tetrahydropyranylation of benzyl alcohol using various catalysts including some reported ones shows the efficiency of this catalyst.

Phosphorus pentoxide as an efficient catalyst for the tetrahydropyranylation of alcohols under solvent-free conditions

A facile and efficient method for the preparation of tetrahydropyranyl ethers from alcohols is improved in solvent-free media. These reactions are catalyzed by P2O5 and afford various tetrahydropyranyl ethers in shorter reaction time, with good to excellent yields (75-95%) at room temperature. This method is also compatible with substrates containing acid-sensitive functional groups.

Network single ion conductors based on comb-branched polyepoxide ethers and lithium bis(allylmalonato)borate

The synthesis of network single ion conductors to obtain single ion conductors with high ambient temperature conductivity and mechanical strength is discussed. The single ion conductors were based on comb-branched polyepoxide ethers and lithium (Li) bis(allylmelonato)borate. The single ion conductors possessed good mechanical strength due to the formation of network structure and the Li/Li symmetric cell cycling showed no concentration polymerization. The results show that the backbone structure of the polyepoxides contributes to the total ionic conductivity and it increases with the increasing side chain length.

Lithium tetrafluoroborate-in acetonitrile (LTAN) catalyzed Ferrier rearrangement - Facile synthesis of alkyl 2,3-unsaturated glycopyranosides?

Treatment of 3,4-dihydro-2H-pyran 1 with various alcohols 2 - 10 furnished the tetrahydropyranyl ethers 11 - 19 in the presence of lithium tetrafluoroborate in acetonitrile (LTAN).

Oligonucleotide analogs with an amino acid or a modified amino alcohol residue

The present invention provides various novel oligonucleotide analogs having one or more properties that make the subject compounds superior to conventional oligonucleotides for use in procedures employing oligonucleotides. The compounds of the invention are oligonucleotide analogs in which the furanose ring of a naturally occurring nucleic acid is replaced with an amino acid or a modified amino alcohol residue. Some embodiments of the novel compounds of the invention are particularly useful for the antisense control of gene expression. The compounds of the invention may also be used as nucleic acid hybridization probes or as primers. Another aspect of the invention is to provide monomeric precursors of the oligonucleotide analogs of the invention. These monomeric precursors may be used to synthesize the subject polynucleotide analogs. Another aspect of the invention is to provide formulations of the subject polynucleotide analogs that are designed for the treatment or prevention of disease conditions. Yet another aspect of the invention is to provide methods for treating or preventing diseases, particularly viral infections and cell growth disorders. The subject disease treatment methods comprise the step of administering an effective amount of the subject polynucleotide analogs for use as antisense inhibitors.

Mild and efficient tetrahydropyranylation of alcohols-catalysis by lithium perchlorate in diethyl ether

Treatment of 3,4-dihydro-2H-pyran 1 with various alcohols 2 - 10 furnished the tetrahydropyranyl ethers 11 - 19 in the presence of 5M lithium perchlorate in diethyl ether (5M LPDE), which is essentially a neutral medium.